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Abstract
Influenza A virus causes seasonal epidemics and periodic pandemics threatening the health of millions of people each year.
Vaccination is an effective strategy for reducing morbidity and mortality, and in the absence of drug resistance, the efficacy
of chemoprophylaxis is comparable to that of vaccines. However, the rapid emergence of drug resistance has emphasized
the need for new drug targets. Knowledge of the host cell components required for influenza replication has been an area
targeted for disease intervention. In this study, the human protease genes required for influenza virus replication were
determined and validated using RNA interference approaches. The genes validated as critical for influenza virus replication
were ADAMTS7, CPE, DPP3, MST1, and PRSS12, and pathway analysis showed these genes were in global host cell pathways
governing inflammation (NF-kB), cAMP/calcium signaling (CRE/CREB), and apoptosis. Analyses of host microRNAs predicted
to govern expression of these genes showed that eight miRNAs regulated gene expression during virus replication. These
findings identify unique host genes and microRNAs important for influenza replication providing potential new targets for
disease intervention strategies.
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Introduction
Influenza A viruses generally cause seasonal epidemics however
they have the potential to cause pandemics associated with
substantial morbidity and mortality [1,2]. Development of
seasonal vaccines is required for influenza virus due to high viral
mutation rates that lead to antigenic drift, and also because of
periodic antigenic shift which can render vaccines less or
ineffective [3]. There are various antiviral drugs that have proven
efficacy in the treatment of influenza infections: two M2 ion
channel inhibitors (amantadine and rimantadine) and several
neuraminidase inhibitors (including zamamivir and oseltamivir)
[4,5,6,7,8,9]. Early treatment with these antiviral drugs reduces
the duration of symptoms and the time to recovery; however, the
use of antiviral drugs is complicated by the emergence of drug
resistant viruses [5,6,10,11,12]. In addition, antiviral drug use may
come with unwelcome effects that could include an increase in
population vulnerability due to lack of seroconversion, as well as
driving drug resistance among circulating strains [11]. Thus, it is
critical to discover new targets for chemoprophylactics and
treatment.
Recent advances in our understanding of RNA interference
(RNAi) have provided a means to perform genome-wide screens to
determine and validate host cell genes that may be required for
influenza virus replication [13,14]. RNAi is an efficient mecha-
nism for the sequence-specific inhibition of gene expression
[15,16], and is mediated by small interfering RNAs (siRNA)
incorporated in the RNA-induced silencing complex (RISC)
where the antisense or guide strand of the siRNA can suppress
protein expression or direct degradation of messenger RNAs that
contain homologous sequences [17,18,19]. Synthetic siRNAs can
be readily developed to target viral or host genes and have been
successfully applied in disease intervention approaches. For
example, siRNA targeting respiratory syncytial virus has shown
efficacy for silencing virus replication [20,21,22,23,24,25], a
feature that has led to RNAi-based clinical trials as a new
therapeutic option [23]. In addition, there are promising results
from targeting host genes, such as the use of siRNA silencing for
the treatment of age-related macular degeneration [26], and in the
case of influenza, inhibiting the host gene CAMK2B prevented
vRNA transcription in vitro [27], and shRNA inhibition of trypsin
also inhibited replication and apoptosis [28]. Recently, several
studies employed genome-wide RNAi screens to identify host
genes required for influenza virus infection and replication
[27,29,30,31,32], and genes have also been identified by random
homozygous gene perturbation [33] and by a proteomic screen
[34]. Although there were few common genes detected among the
studies, meta-analysis revealed that influenza virus was co-opting
many of the same host cell pathways [27,29,30,31,32,35]. Thus,
the inability to find the same genes among the studies is not
unexpected given that multiple genes may be affected in the same
host cell pathway, that the tempo of gene expression may vary
among the cell lines studied, and that differences can be attributed
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37169to variations in methodologies, viruses, and cell lines used among
the studies [27,29,30,35].
Of the host genes known to affect influenza virus, the proteases
are important for infection and replication. Proteases may affect
virus infection and replication in several ways including viral entry
and hemagglutinin (HA) processing [36,37,38,39], degradation of
viral components for MHC presentation [40], cap-snatching [41],
induction of apoptosis [42], and by increasing vascular perme-
ability aiding in the development of systemic infection in cases of
severe infection [43]. However, it remains unclear which protease
genes are essential in the biology of influenza virus replication.
In addition to host gene involvement during viral infection, the
tempo of host gene expression may be altered by a variety of
factors, such as by microRNAs (miRNA). Host miRNAs are
similar to siRNAs in their silencing mechanism, but miRNAs are
generated in the nucleus from short hairpin precursors and must
be processed and exported before entering the RISC pathway
[44]. miRNAs can be generated by the virus [45,46] or the host
and can silence genes by similar mechanisms to siRNAs; however,
unlike siRNA silencing, miRNA sequences do not need to be
homologous to the target mRNA [44]. Little is known about the
role of miRNAs during virus infection, however host-derived
miRNAs have been shown to negatively affect influenza replica-
tion [47] and miRNAs have even been used as therapeutics
[48,49]. We considered that host miRNAs might also have a role
in host gene modulation during influenza infection.
To comprehensively determine the host proteases required by
influenza virus for infection and replication, a siRNA screen of all
known 481 protease genes was performed in human lung epithelial
(A549) cells using the influenza virus, A/WSN/33. Twenty-four
primary gene hits were found in the siRNA screen of which five
(ADAMTS7, CPE, DPP3, MST1, and PRSS12) were validated as
Figure 1. RNAi of 5 host protease genes down-regulated influenza virus replication. A: A549 cells were reverse transfected with 50 nM of
siRNA (SMARTpool) specific for the indicated genes (ADAMTS7, CPE, DPP3, MST1, PRSS12). After 48 hours, cytotoxicity was determined by adenylate
kinase (AK) release. Cells treated with the siTOX control were considered 100% cytotoxic and all values were normalized to siTOX. RLU=relative
luciferase units. * p,0.05 vs siNEG, ** p,0.01 vs siNEG, ***p,0.005 vs siNEG; siTOX vs all samples: p,0.001 (not shown). Line shows 20% of siTOX
control. B: A549 cells were reverse transfected with 50 nM of siRNA (SMARTpool) specific for the indicated genes (ADAMTS7, CPE, DPP3, MST1,
PRSS12). After 48 hours, cells were infected with A/WSN/33 at an MOI of 0.001. 48 hours post-infection, cells were fixed in 4% formaldehyde and
stained with an anti-NP (green) monoclonal antibody followed by counterstain with DAPI (blue.) Positive (+) control: siMEK, negative (2) control:
siNEG. Magnification is 206(bar is 100 microns). C: Cells were transfected with 100 nM of a novel siRNA targeting a different seed site from the
SMARTpool used in the primary screen and infected as in B. After 48 hours of infection, cellular supernatant was tested for infectious virus production
by a modified TCID50. Data is expressed as TCID50/ml. Data is representative of two independent experiments. (*p,0.05 vs siNEG).
doi:10.1371/journal.pone.0037169.g001
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genes were linked to cAMP responsive binding element (CREB),
NF-kB, and apoptosis pathways, thus we examined and verified
host gene regulation of these pathways. As the tempo of host gene
expression is governed by miRNAs which have important roles in
regulating host genes during viral infection and replication
[45,50,51], an additional analysis was performed to identify
miRNAs that might potentially regulate the five validated host
genes required for influenza virus replication. A library of miRNA
antagonists was used to confirm miRNA regulation, and several
miRNAs were identified to affect virus replication and host gene
regulation, notably miR-1254, miR-106B, miR-106B*, miR-124-
a, and miR-124*. This finding shows varied miRNA expression
patterns associated with the regulation of various genes involved in
global host cell pathways governing inflammation (NF-kB),
cAMP/calcium signaling (CRE/CREB), and apoptosis, and adds
to our understanding of how miRNAs may govern host gene
regulatory networks involved in the response to influenza virus
replication.
Results
Human protease genes required for influenza replication
A primary RNAi screen of 481 host protease genes in a human
type II respiratory epithelial cell line (A549) identified 24 genes
important for A/WSN/33 influenza virus replication (Figure S1).
The gene hits identified were $1.5s and #21.5s from the mean
Z-score. Endpoint validation of the gene hits in the primary screen
included influenza nucleoprotein (NP) cell localization determined
by immunohistochemistry, determining the level of infectious virus
by TCID50 assay, as well as influenza matrix (M) gene copy
number determined by qPCR (data not shown). For validation of
primary gene hits, a novel siRNA targeting the same gene but at a
different seed site (Table 1) was required to produce the same
phenotype as observed in the screen. Protein levels of the protease
genes were assessed to ensure that RNAi silencing was decreasing
target gene expression (Figure S2). After validation, five genes were
identified that decreased virus replication when silenced:
ADAMTS7, CPE, DPP3, MST1, and PRSS12 (Table 1).
Silencing of these protease genes did not cause cytotoxicity in
A549 cells compared to the cytotoxicity (siTOX) control. siMEK
(an siRNA targeting MAP2K) and siNEG (a negative, non-
targeting siRNA control) both displayed low level cytotoxicity
possibly due to the importance of MEK in cellular signaling, and
the induction of an inflammatory response to siNEG due to off-
target effects (Figure 1A). Silencing of the five validated genes
resulted in considerably decreased influenza NP staining com-
pared to the negative (2) control, and was consistent with low NP
staining in cells treated with the positive (+) siRNA control, siMEK
(Figure 1B). The level of infectious virus from A549 cells treated
Table 1. Human protease gene hits.
Gene Name Accession number siRNA sequences Function
ADAMTS7 ADAM metallopeptidase with
thrombospondin type 1, motif 7
NM_014272 SMARTpool*:
GCGAGGACCCGGAGAAGUA
GAACGUGGGCUGUGACUUC
CAACGAGGACUACUUCAUU
GCAGAUACUGUGUGGGUGA
Novel siRNA for Validation
#:
CCAAGGACAUUAUCGACUU
Role in inflammation of
extracellular matrix
[56,77,78,79]
CPE Carboxypeptidase E NM_001873 SMARTpool*:
GAAAGAAGGUGGUCCAAAU
GCUUAUACCUGGAAACUAU
GGAAUAGACCACGAUGUUA
GGAUGCAAGACUUCAAUUA
Novel siRNA for Validation
#:
GAUGAGACGCGGAGUGGUA
Role in local opioid network
in the lung [57,80,81,82]
DPP3 Dipeptidyl-peptidase 3 NM_005700 SMARTpool*:
ACACGGUGCUGCUGCGUAA
GAGGGAAUCACCACCUAUU
GCAGCAAGAUCCGGUCUGU
GCUCAGACGUGCAGCUUCU
Novel siRNA for Validation
#:
GAUCCUUCUCUGAGCGUUU
Role in inflammation and
apoptosis [83,84,85]
MST1 Macrophage stimulating 1
(hepatocyte growth factor-like)
NM_020998 SMARTpool*:
GUACGGACCUGCAUCAUGA
GGAAUGGCCUGGAAGAGAA
GCUGUGACCUCUUCCAGAA
CGACAACUAUUGCCGGAAU
Novel siRNA for Validation
#:
GACCAAAGGUACGGGUAAU
Role in inflammation and
response to tissue injury
[55]
PRSS12 Neurotrypsin, motopsin NM_003619 SMARTpool*:
GGACUGAGCUGAAUACAUA
GAUGAUGGAUGGACUGAUA
GAGCAUAACUGUGGCCAUA
GGACGAGCCUAUUCAAGAA
Novel siRNA for Validation
#:
GAGCAAGAACCAUGGCUUA
Unknown
*: Refers to the pool of four siRNAs used in the primary screen.
#: Refers to the individual siRNA used for the validation step.
doi:10.1371/journal.pone.0037169.t001
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genes was greatly (siCPE, siMST1 and siPRSS12) and significantly
(p,0.05; siADAMTS7 and siDPP3) reduced (Figure 1C). Influ-
enza virus M gene levels reflected the low level of infectious virus
and NP staining observed for A549 cells treated with siRNAs
targeting the five validated genes, as well (data not shown).
Host genes validated with a clinical influenza virus isolate
Since A/WSN/33 was used in the primary and secondary
screens because of its ability to grow in the absence of trypsin, a
feature facilitating high throughput screening, cross-validation of
ADAMTS7, CPE, DPP3, MST1, and PRSS12 genes was
performed in A549 cells with A/New Caledonia/20/99. Using
the same siRNAs previously used to validate the genes (Figure 1C),
A549 cells treated with 100 nM of the siRNAs significantly
(p,0.05) reduced A/New Caledonia/20/99 virus replication
(Figure 2). The differences in viral titer were at least 1.5 logs
lower compared to siNEG-treated cells for all five genes examined.
These results show that ADAMTS7, CPE, DPP3, MST1, and
PRSS12 contribute to influenza A virus replication, and provide
promising disease intervention targets.
Figure 2. RNAi of individual host protease genes down-
regulates replication of a clinical influenza isolate. A549 cells
were reverse transfected with 100 nM of the novel siRNA targeting
siADAMTS7, siCPE, siDPP3, siMST1, and siPRSS12. After 48 hours, cells
were infected with A/New Caledonia/20/99 at an MOI of 0.1 in the
presence of 1 ug/ml TPCK-trypsin. After 48 hours of infection, cellular
supernatant was tested for infectious virus production by a modified
TCID50. Data is expressed as TCID50/ml. Data is representative of two
independent experiments. (*p,0.05 vs. siNEG).
doi:10.1371/journal.pone.0037169.g002
Figure 3. Analysis of host gene involvement in major cellular pathways. A: A549 cells were reverse cotransfected with CRE/CREB reporter
plasmid or the appropriate control plasmid and 100 nM of the novel siRNA. After 24 h incubation, the transfection media was replaced with culture
media. Cells were mock infected or infected with A/WSN/33 at an MOI of 0.001 the following day. After 24 h, culture supernatant was analyzed for
luciferase expression. Luciferase units were normalized to Renilla expression. * p,0.05, ** p,0.01 compared to siNEG control (mock), # p,0.05, ##
p,0.01 compared to siNEG control (A/WSN/33) B: A549 cells were reversed cotransfected with NF-kB reporter plasmid or the appropriate control
plasmid and 100 nM of the novel siRNA. After 24 h incubation, the transfection media was replaced with culture media. Cells were mock infected or
infected with A/WSN/33 at an MOI of 0.001 the following day. After 24 h, culture supernatant was analyzed for luciferase expression. Luciferase units
were normalized to Renilla expression. * p,0.05, ** p,0.01 compared to siNEG control (mock), # p,0.05, ## p,0.01 compared to siNEG control (A/
WSN/33). Data is representative of three independent experiments.
doi:10.1371/journal.pone.0037169.g003
Figure 4. RNAi of DPP3 (siDPP3) inhibits influenza replication
by modulation of apoptotic genes. A549 cells were reverse
transfected with 50 nM of siDPP3 or siNEG. After 48 hours, cells were
infected with A/WSN/33 at an MOI of 0.001. After 18 hours of infection,
cellular RNA was isolated and apoptosis gene expression profiles were
determined by array. Gene expression was normalized to GAPDH levels.
Silencing DPP3 resulted in upregulated levels of the pro-apoptotic
genes BCL2L10, TNFSF10, TNFSF25 and TNFSF8. Data is representative
of three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0037169.g004
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interest were evaluated for their effect on host gene hits by qPCR. A549 cells were treated with the appropriate miRNA inhibitor (25 nM) for 24 hours.
Cellular RNA was isolated 24 hpi and evaluated by qPCR for host gene expression using a SYBRgreen assay with gene-specific primers. Gene
expression was compared to cells transfected with siNEG (for siRNA) or NEG (non-targeting miRNA inhibitor) at the equivalent concentration. Data is
normalized to GAPDH expression. miRNAs indicated on the x-axis refer to inhibition of those miRNAs. A: ADAMTS7 expression levels, B: CPE, C: DPP3,
D: MST1, E: PRSS12. Data is representative of two independent experiments. (*p,0.05 versus siRNA treatment.).
doi:10.1371/journal.pone.0037169.g005
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affect influenza replication
Expanding from the primary screen toward defining host cell
pathways involved in influenza virus replication requires assess-
ment of the signaling pathways, molecular networks, and
biological processes that are linked to the five validated host
genes. Dynamic pathway analysis identified three major pathways
for the five validated genes, i.e. NF-kB pathway, CRE/CREB
signaling pathway, and cellular apoptosis (Figure S3). To verify the
host genes in these pathways, A549 cells were transfected with a
luciferase assay reporter plasmid governed by the promoter of
interest linked to a firefly luciferase gene. The level of pathway
activation was determined by luciferase expression, which was
normalized to a control plasmid expressing Renilla luciferase to
account for transfection efficiency. Pathway analysis suggested that
MST1 and PRSS12 genes participate in the CRE/CREB
signaling pathway. RNAi of MST1 by siRNA targeting (siMST1)
led to a significant (p,0.05) increase in CRE/CREB signaling
compared to the siNEG and CRE controls in the presence or
absence of influenza virus infection (Figure 3A). RNAi of PRSS12
by siPRSS12 did not affect CRE/CREB activation relative to
controls. Interestingly, RNAi of DPP3 using siDPP3 significantly
(p,0.05) increased CRE/CREB activation under mock-infected
conditions despite DPP3 not being implicated in the CRE/CREB
pathway, and silencing of ADAMTS7 significantly (p,0.05)
abrogated CRE/CREB activation during infection. Pathway
analysis also indicated that ADAMTS7, CPE, and MST1 genes
were potentially involved in the NF-kB activation pathway (Figure
S3). siADAMTS7 significantly (p,0.01) abrogated NF-kB activa-
tion regardless of infection or mock-treatment (Figure 3B).
Interestingly, a similar finding was observed for DPP3, a gene
not previously linked to the NF-kB signaling pathway by our
analysis. siCPE did not affect NF-kB activation under mock
conditions, but during infection NF-kB activation levels were
significantly (p,0.05) downregulated. siMST1 also had a negative
effect on NF-kB activation regardless of infection. Elevated NF-kB
levels were also seen in controls receiving the NF-kB plasmid alone
but this was not significant compared of siNEG controls.
Dynamic pathway analysis predicted DPP3 to be involved in
apoptotic pathways (Figure S3), and as a luciferase/Renilla
pathway reporter system was unavailable, a human apoptosis
array was performed to determine the level of mRNA expression
of various pro- and anti-apoptotic host genes in relation to DPP3
expression (Figure 4). After confirming RNAi silencing (.95%) of
DPP3 by PCR (data not shown), gene expression was compared in
cellular RNA extracted from infected A549 cells treated with
either siDPP3 or siNEG (50 nM). While most genes tested did not
vary in expression levels relative to siNEG-treated cells, four pro-
apoptotic genes were found to be substantially increased when
DPP3 was silenced: BCL2L10, TNFSF10, TNFRSF25, and
TNFSF8. Of these four genes, TNFSF10 was significantly
(p,0.05) increased 6-fold, and TNFSF8 was significantly
(p,0.05) increased 5-fold compared to siNEG control treated
cells. TNFRSF25 was substantially increased as well. These
findings show that inhibition of DPP3 expression initiates higher
expression of pro-apoptotic factors, features that may negatively
impact influenza virus replication and associated modulation of
cellular apoptosis. Silencing of the other four target protease genes
did not significantly affect levels of pro- or anti-apoptotic genes
compared to cells treated with siNEG as predicted by the
Ingenuity pathway analysis, although TNFSF10 was substantially
increased when cells were treated with siADAMTS7 (Table S1).
miRNAs govern host genes required for influenza
replication
Pathway analysis of the five validated host genes revealed
potential miRNA interaction (Figure S4) with eight miRNAs (miR-
1254, miR-1272, miR-17-5p, miR-17-3p, miR-106B, miR-106B*,
miR-124-a, and miR-124*). To determine the role of these
miRNAs in regulating ADAMTS7, CPE, DPP3, MST1, and
PRSS12, A549 cells were treated with miRNA hairpin inhibitors
as previously described [52], or treated with a negative control
from C. elegans that shares no homology with known human
miRNA sequences, and gene expression levels determined by
qPCR. As gene modulation by miRNAs is usually subtle and
multi-targeted, the effect of the miRNA inhibitors on host gene
mRNA levels was determined 24 hours post-treatment. All 8
miRNA inhibitors were tested for their effect on each of the 5
validated genes; however, only those inhibitors that affected gene
expression are shown (Figure 5). At 24 h post-treatment,
ADAMTS7 gene expression levels increased 20-fold when miR-
106B was inhibited, and 40-fold when miR-124* was inhibited
(Figure 5A). Treatment with siRNA targeting the gene examined
was performed as a control. CPE expression was slightly decreased
by miRNA inhibitors, as there was no response above 1.0
(Figure 5B). In contrast, inhibition of miR-106B and miR-124*
resulted in a .20-fold and .40-fold increase of DPP3 gene
expression, respectively (Figure 5C), while miR-1254, miR-1272,
and miR-17-3p inhibition caused a decrease of DPP3 expression.
MST1 expression was increased to similar levels as DPP3 with the
same miRNA inhibitors, while the other miRNA inhibitors
resulted in a slight (but significant for miR-17-3p) decrease in
expression (Figure 5D). Finally, PRSS12 expression levels were
significantly (p,0.05) increased in response to miR-106B inhibi-
tion, but a slight decrease was detected by inhibition of miR-1254
(Figure 5E). These results show the same miRNAs can regulate
different genes both subtly and robustly.
Given the evidence that miR-1254, miR-1272, miR-17-5p,
miR-17-3p, miR-106B, miR-106B*, miR-124-a, and miR-124*
are involved in governing aspects of ADAMTS7, CPE, DPP3,
Figure 6. Effect of miRNA inhibition on influenza replication.
A549 cells were treated with the appropriate miRNA inhibitor (25 nM)
for 48 hours, followed by infection with A/WSN/33 (MOI=0.001).
Cellular supernatant was tested for infectious virus production by a
modified TCID50 48 hpi. Data is expressed as TCID50/ml and is
representative of two independent experiments.
doi:10.1371/journal.pone.0037169.g006
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miRNAs in the regulation of influenza virus replication was
determined (Figure 6). A549 cells were treated with individual
miRNA inhibitors and the cells infected with A/WSN/33 to
determine the effect on virus replication (Figure 6). Of the 8
miRNA inhibitors tested, inhibition of miR-106B was associated
with a decrease in influenza virus replication, while inhibition of
miR-124 resulted in an increase in virus replication with respect to
the negative control. Inhibition of the other eight miRNAs had
more subtle effects with slight increases or decreases of influenza
virus replication. The decrease of virus replication associated with
inhibition of miR-106B is likely associated with a decrease of CPE
gene expression as RNAi silencing of CPE was associated with low
levels of virus replication (Figures 1 and 2). The level of virus
replication was confirmed by qPCR M gene levels and was
consistent with the findings observed in Figure 5 (data not shown).
The results show that some of the miRNAs modulate host genes
critical for influenza virus replication, thus it likely that the tempo
of host gene expression is differentially regulated in response to
influenza virus infection. Further, the results provide evidence that
targeting miRNAs may offer an alternative disease intervention
approach to control influenza virus replication.
Discussion
Some human proteases are known to have a direct function in
the replication of influenza virus [38,39], but the role of other
proteases in the biology of virus replication and host cell pathways
they affect are not fully elucidated. To better understand protease
gene requirements for influenza virus replication, and discover
novel disease intervention targets, we conducted an RNAi screen
of 481 genes comprising the human protease genome and
validated five genes, ADAMTS7, CPE, DPP3, MST1, and
PRSS12 that are required for influenza replication. The primary
and secondary RNAi screens were performed with A/WSN/33
influenza virus because of its ability to replicate in the absence of
trypsin in a type II respiratory epithelial (A549) cell line. All five
genes showed reduced A/WSN/33 titers and some showed a
substantial decrease in NP staining to the level where NP was not
detected using a NP-specific monoclonal antibody. This may have
been due to an inability of the virus to reenter the host cells for
subsequent infection as a consequence of protease gene silencing.
To confirm the findings for WSN/33 infection, the five validated
genes were assessed against a clinical influenza virus strain, i.e. A/
New Caledonia/20/99. RNAi silencing of all five genes resulted in
decreased levels of A/New Caledonia/20/99 replication. Al-
though previous RNAi host factor screens for influenza virus
replication did not identify any of the five protease genes in this
study, the same host cell pathways were identified which included
the genes validated in this study [27,29,30,31,32]. Specifically, our
pathway analysis for this study showed that ADAMTS7, CPE,
DPP3, MST1, and PRSS12 were involved in three previously
identified host cell pathways, specifically CRE/CREB signaling,
NF-kB activation, and apoptosis. It is likely that different pathway
interaction is co-opted by the virus at different stages in the virus
replication process, but further study is needed to determine the
exact process. An additional caveat may be the use of an
immortalized cell line to identify gene hits. Clonal cell lines can
have misregulated gene expression relative to primary cells,
particularly for genes involved in cell growth and differentiation
[53]. Use of a primary human cell line to perform this study, e.g.
normal human bronchial epithelial (NHBE) cells may be more
desirable; however, primary cells often have reduced transfection
efficacy and issues with maintenance of a uniform stage of
differentiation that makes it difficult to perform high-throughput
screening [35]. Therefore, it is possible that some genes discovered
may not translate to a primary cell line, so further evaluation is
needed to confirm the results of this study.
CRE/CREB signaling is an important cellular process that
serves a variety of functions. Most notably with respect to influenza
infection, CRE/CREB signaling has been shown to activate
protein kinase A (PKA) and thus have a role in protein synthesis
[54]. In this study, MST1 and PRSS12 were implicated in CRE/
CREB signaling; however, in response to influenza infection, CRE
signaling levels in cells treated with siPRSS12 were unchanged
compared to both pathway reporter and siNEG controls.
However, RNAi of the MST1 gene resulted in significantly higher
CRE signaling levels regardless of infection. These findings may
suggest that MST1 is involved in some aspect of CRE signaling or
the cAMP response, and without MST1, the calcium response
element is not activated.
ADAMTS7, CPE, and MST1 have been shown to have a role
in tissue injury and inflammation [55,56,57], and pathway analysis
performed in this study identifying their linkage to NF-kB pathway
activation is consistent with these earlier findings. However, there
was no significant effect of these genes on the NF-kB pathway
relative to controls. However, A549 cells treated with siRNAs
targeting ADAMTS7 and DPP3, a gene not predicted to be
involved in the NF-kB pathway, resulted in complete abrogation
of NF-kB regardless of influenza infection. This finding suggests
that NF-kB signaling may involve ADAMTS7 and DPP3. As
ADAMTS7 plays a role in maintenance of the extracellular matrix
[56] and DPP3 is a metallopeptidase, it is possible that silencing
these genes is decreasing the inflammatory response because less
damage is being done to basement tissue. ADAMTS7 has also
been shown to be upregulated by TNF-a and IL-1b secretion [56],
both of which are activated upon influenza infection [43].
DPP3 is involved in apoptosis modulation and is over-expressed
in cancerous cells [58]. RNAi of the DPP3 gene was performed to
evaluate the effect on apoptotic gene expression. The results
showed induction of BCL2L10, TNFSF10, TNFRSF25 and
TNFSF8 pro-apoptotic genes. BCL2L10 is a pro-apoptotic gene
that interacts with caspase 9 to signal apoptosis [59], and TNFSF8
and TNFRSF25 are involved in the pro-inflammatory response
through NF-kB signaling [60,61]. TNFSF10, also known as
TRAIL, has been shown to be involved in H5N1 virus-induced
apoptosis in human monocyte-derived macrophages [62]. Since
DPP3 silencing resulted in a sharp decrease of influenza
replication as quantified by TCID50 and NP staining, the findings
suggest that reducing DPP3 gene expression causes influenza virus
infected cells to initiate apoptosis without interference by the
known anti-apoptosis activities of the influenza NS1 protein [3]. It
is possible that without the NS1-mediated apoptosis delay, the
virus is not able to replicate and bud before the host cell is
eliminated. Furthermore, as NF-kB appears to have a role in
apoptosis modulation, the effect of DPP3 silencing on NF-kB
activation observed in this study is predictable and consistent with
earlier findings [63].
Host gene expression is governed by miRNAs [44,64], thus it is
important to understand potential miRNA regulation of host genes
validated as required for influenza virus replication. The results
from the miRNA hairpin inhibitor studies showed that targeting
the predicted miRNAs had a considerable and significant outcome
on most host gene expression. For example, inhibition of miR-
106B and miR-124* resulted in 20-fold and 40-fold increased
ADAMTS7 gene expression levels, respectively, while CPE gene
expression was slightly reduced by miRNA inhibitors. As expected,
some miRNA inhibitors had differential effects on host genes
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miR-106B had little effect on CPE gene expression, but
dramatically increased DPP3 gene expression. These findings
show that expression of host genes required for influenza virus
replication can be regulated by multiple miRNAs, and suggests
that targeting miRNAs to regulate host gene expression may be a
strategy to regulate influenza virus replication.
As predicted from the host gene expression studies, miRNA
inhibitors also affected influenza virus replication. For example,
inhibition of miR-106B, a miRNA known to cause cell cycle arrest
when inhibited in a laryngeal cancer model [65], resulted in
substantially decreased virus replication. Human papillomavirus
oncoproteins E6 and E7 have also been reported to dysregulate
miR-106B [66]. Inhibition of miR-124-a resulted in an increase of
influenza virus replication relative to the negative control.
Although miR-124-a was not found to regulate any of the 5 host
protease genes from our screen, it is reported to have a putative
target in both swine influenza virus and the 2009 pandemic H1N1
strain [67]. Inhibition of other miRNAs also subtly modulated
infectious virus levels, but not to a level significantly different from
the NEG control. In this study, inhibition of miR-106B increased
ADAMTS7, DPP3, MST1 and PRSSS12 gene expression, but
subtly reduced CPE gene expression, an effect that resulted in
reduced influenza virus replication, implying the effect of miR-
106B inhibition on CPE may be dominant. Additionally,
inhibition of miR-1254 resulted in slightly decreased CPE,
DPP3, MST1 and PRSS12 gene expression levels, and this
translated to slightly decreased influenza virus replication. Since
none of the 5 validated genes were increased by inhibition of miR-
124-a, it is likely miR-124-a affects influenza replication through
other genes yet identified. These findings indicate that while
miRNAs do modulate host gene expression, they likely modulate
influenza replication indirectly and perhaps at different points in
the replication pathway. Further study is needed to validate
miRNA involvement and mechanism of virus inhibition or
assistance. Taken together, these findings suggest novel targets
and potentially new therapies for regulating influenza replication
and the pathways co-opted during infection.
Materials and Methods
Cells and virus stocks
A549 cells (ATCC CCL-185) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (HyClone, Logan, UT)
containing 5% heat-inactivated FBS (HyClone, Logan, UT). Cells
were frozen in 10% DMSO and 90% FBS to create one stock of a
single cell passage that was used for the entire screen. A stock of
MDCK cells (ATCC CCL-34) was also propagated and stored
using the same conditions. A/WSN/33 (H1N1) influenza virus
was used for the primary siRNA screen as this virus has the ability
to replicate without the need for exogenous trypsin [68]. For the
validation studies, A/New Caledonia/20/99 (H1N1) influenza
virus was also used. All viruses were propagated in 9-day-old
embryonated chicken eggs as previously described [69]. Viruses
were titrated in MDCK cells and titers calculated by the method
developed by Reed and Muench [70].
Protease library screen
A primary screen using four pooled siRNAs to target each gene
of the 481 genes in the human protease library (SMARTpool;
Dharmacon ThermoFisher, Lafayette, CO) was performed using
A/WSN/33 influenza virus and type II human alveolar pneumo-
cytes (A549 cells) similar to a method previously described [27].
siRNAs were resuspended in Dharamcon siRNA buffer to a
concentration of 1 uM and stored at 280uC until use. The screen
was conducted in two steps, a primary screen targeting all 481
human protease genes, followed by a smaller-scale validation
screen of the primary hits to confirm the genes identified were
essential for influenza virus replication. In all studies, a siRNA
targeting the MEK gene (siMEK), a well-characterized human
kinase gene important for influenza replication [4,71], was used to
control for the transfection efficiency and host gene silencing. A
non-targeting siRNA control (siNEG) was also used in all assays.
The siRNA SMARTpool library constituents, siMEK, and siNEG
transfected A549 cells at .85% efficiency, and a few (,2%)
siRNA pools targeting HP genes induced cytotoxicity as deter-
mined by adenylate kinase (AK) release in the cell culture
supernatant [72,73] and by visual inspection of cell morphology.
A549 cells were reverse transfected with the siRNA 48 hours
before infection with influenza A/WSN/33 (MOI=0.001). The
amount of infectious virus was measured 48 hpi by titration of
A549 cell supernatant on MDCK cells, and the results normalized
to siNEG-treated cells. All assays were run in duplicate and the
entire screen assay was repeated twice. Both plate-based controls
and assay-wide controls, e.g. siMEK, siNEG, and siTOX, were
included on each individual assay plate. The results were
normalized to the plate median for the SMARTpools. After
excluding cytotoxic siRNAs based on detection of AK, primary
screen data was subject to analysis. The primary screen, performed
as two independent studies, was analyzed using a scaling
methodology that sets the non-targeting control siRNA (siNEG)
at an arbitrary value of 1.0, and the negative control siTOX at
zero. siRNAs targeting host genes were assigned a score based on
the distribution of these values. Wells in the primary screen with a
percent of differentiation $|1.5| standard deviations from the
plate mean in both duplicate assays were considered primary hits.
Of the 481 HP genes targeted, twenty-four genes were identified as
‘‘primary hits’’. Hits that caused greater than 20% cytotoxicity in
A549 cells were excluded (Figure 1A). Z-scores were computed
based on this data for each gene hit and those $1.5s and
#21.5s were considered for validation.
Reverse transfection
Lyophilized siRNAs in 96-well plates were diluted with HBSS
(HyClone, Logan, UT) and allowed to incubate for 5 minutes.
Dharmafect-1 transfection reagent (Lafayette, CO) and HBSS
were added such that each well received 0.004 ml of transfection
reagent and 0.096 ml of HBSS. The siRNA/transfection reagent
mix was allowed to incubate for 20 minutes at room temperature
after which 0.08 ml of 1.5610
4 A549 cells suspended in DMEM/
5% FBS was added to each well, and the plate incubated for
48 hours at 37uCi n5 %C O 2. The final concentration of siRNA
for all primary screen transfections was 50 nM.
Cytotoxicity and virus infection
To determine if siRNA gene silencing was cytotoxic, the cell
supernatants from siRNA transfected A549 cells were analyzed for
adenylate kinase (AK) using a Toxilight kit (Lonza, Rockland,
ME). Results were normalized to a siTOX control, i.e. a siRNA
control (Dharmacon) causing complete cell death by 48 hours.
siRNA transfected cells with luminescence greater than or equal to
20% of the siTOX control were not considered for further
evaluation. A549 cells were subsequently infected with A/WSN/
33 at an MOI of 0.001 pfu/cell. Cells were incubated for 48 hours
at 37uC/5% CO2.
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Virus titers in siRNA-treated A549 cells infected with A/WSN/
33 were determined by modified TCID50 or hemagglutination
assay (HA). Briefly, virus infected A549 cell culture supernatants
were serially diluted ten-fold, and added to MDCK cells. The
MDCK cell plates were incubated for 72 h, followed by an HA
using 0.5% chicken red blood cells as previously described [74].
To further identify gene hits the cells were screened for
nucleoprotein (NP) by IHC staining and evaluated using high
content analysis. For NP staining, the cells were fixed with 3.7%
formaldehyde and stained with anti-NP monoclonal antibody
(5 ug/ml; H16-L10-4R5) and the antibody staining detected using
Alexa Fluor 488 labeled goat anti-mouse IgG (1 ug/ml; Invitro-
gen, Carlsbad, CA). Cells were counterstained with DAPI (2 ug/
ml) (Invitrogen, Carlsbad, CA) and visualized by immunofluores-
cent microscopy (206, EVOS digital inverted fluorescent micro-
scope, Advanced Microscopy Group, Bothell, WA). As an
additional hit identification endpoint, real-time qRT-PCR analysis
was performed to quantify influenza M gene copy number in the
cells as previously described [75]. Briefly, RNA was purified using
the RNeasy kit (Qiagen, Valencia, CA), and cDNA was
synthesized using a SuperScript First Strand cDNA synthesis kit
(Invitrogen, Carlsbad, CA) and appropriate primer/probe set [75]
to detect the M gene. PCR was performed using the amplification
cycle: 10 minutes at 95uC followed by 40 cycles of 95uC for
30 seconds, 60uC for 1 minute, and 72uC for 30 seconds. M gene
copies were normalized to the siNEG control.
Validation of gene hits
Individual novel siRNAs (Dharmacon) were used to target a
different seed site on the same gene for gene hits identified during
the primary screen (Table 1). Gene silencing was confirmed by
qPCR using SybrGreen (Qiagen, Valencia, CA) to detect the
dsDNA product allowing for quantification of gene silencing
relative to cells treated with the siNEG control. Primers targeting
each individual hit were compared to control GAPDH levels. For
phenotype validation, A549 cells were transfected with 100 nM
siRNA, incubated 48 h at 37uCi n5 %C O 2, infected with A/
WSN/33 (MOI=0.001), and the amount of infectious virus was
measured 48 hpi by TCID50 and NP staining assays to validate the
screen phenotype previously observed. From the primary gene
hits, five genes essential for influenza virus replication were
validated using the novel siRNAs. The five genes were also tested
using A/New Caledonia/20/99 at an MOI of 0.001 as described
above; however infection was done in the presence of TPCK-
trypsin (1 ug/ml).
Western blot
To determine protein levels in A549 cells treated with siRNA
specific for the target protease genes, A549 cells were untreated,
treated with 50 nM of the siNEG control, or treated with 50 nM
of the appropriate siRNA. After 72 hours, cells were lysed in 1%
TritonX-100 and proteins from total cell lysate were separated on
a 4–20% Tris-HCl precast SDS PAGE gel (BioRad, Hercules, CA)
and transferred to a PVDF membrane. Membranes were blocked
in 5% BSA/TBS- 0.05% tween and incubated with 1 ug/ml
rabbit polyclonal primary antibodies to ADAMTS7, CPE, DPP3,
MST1, or PRSS12 (Abcam, Cambridge, MA). A goat anti-rabbit
alkaline phosphatase-conjugated secondary antibody (Invitrogen)
was used to visualize the proteins.
Host cell pathway analysis
To survey the spectrum of host cell pathways that may be linked
to the validated gene hits, pathway analysis was performed using
Ingenuity Pathway Analysis software (Ingenuity Systems, http://
www.ingenuity.com). The results provided network modeling of
the validated genes and identified several functional groups (NF-
kB, CRE/CREB signaling, apoptosis) linked to protease gene
expression, host cell miRNA regulation, and influenza replication.
Reporter system assays
Reporter plasmids used to confirm pathway were obtained from
SABiosciences/Qiagen as a dual luciferase Cignal Reporter Assay
Kit. The reporters consisted of a transcription factor of interest
linked to a firefly luciferase gene, a positive control plasmid
(luciferase linked to a CMV promoter), and a negative control
plasmid (luciferase with no promoter). A549 cells were co-
transfected with 100 nM of siRNA and 100 ng of the appropriate
plasmid (reporter, positive, or negative control plasmids) using
either the SureFECT (SABiosciences) or Attractene (Qiagen)
transfection reagents. As a transfection control, the plasmid kit also
contains a Renilla luciferase plasmid fused to a CMV promoter,
and all data was normalized to Renilla luciferase expression. After
24 h of transfection, cells were allowed to rest for one day and then
infected with A/WSN/33 (MOI=0.001) for 24 h. Cell lysate was
taken and luciferase expression was measured using a Safire2
Microplate reader (Tecan, Ma ¨nnedorf, Switzerland).
Apoptosis array
A human apoptosis array was obtained from SABiosciences/
Qiagen. A549 cells were transfected with 50 nM of either the
appropriate siRNA or siNEG. After 48 h, cells were infected with
A/WSN/33 at an MOI of 0.001. RNA was isolated 18 hpi, a time
point chosen because it is late enough for apoptosis modulation to
become evident at the transcriptional level, but sufficiently early
such that cells were not destroyed [76], and then treated with
DNase I to remove any genomic DNA. cDNA was synthesized
using an RT
2 First Strand Kit (SABiosciences) and PCR was
performed using RT
2 SYBR Green Master Mix (SABiosciences)
per the manufacturer protocol. Data was analyzed by calculating
2
(2DDCt). Silencing of the protease genes relative to siNEG-treated
cells was confirmed for each independent experiment.
miRNA studies
A library of miRNA hairpin inhibitors synthesized as RNA
oligonucleotides with novel secondary structure designed to inhibit
the function of endogenous miRNA, and chemically enhanced to
improve efficacy and longevity (miRIDIAN, Dharmacon, Lafay-
ette, CO) were used to target host cell miRNAs identified as
potential regulators of host genes validated as important for
influenza virus replication. miRNA mimics were not used since
treatment with mimics results in extremely high concentrations of
miRNA relative to biological levels. In these studies, A549 cells
(1.5610
4) were transfected with 25 nM of an appropriate miRNA
inhibitor using Dharmafect-1 per the manufacturer’s protocol.
After 48 h, the cells were infected with A/WSN/33 at an MOI of
0.001 for an additional 24 h or 48 h. Viral replication was assayed
by TCID50 and qPCR for M gene as described above. Gene
specific primers were also used to quantify changes in host gene
expression in cells receiving the miRNA inhibitors using Sybr-
Green as described above.
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The primary siRNA protease gene screen was performed
independently and in duplicate. HA results for each gene were
assigned values 0–8 based on the dilution of the HA readout. HA
values were normalized to the average of the siNEG control
readout per plate. Robust z-scores (Z=xi2x/sx) were used as the
normalizing method and calculated for each gene to determine
hits based upon the standard deviation where xi is the raw
measurement on the ith siRNA, and sx are the mean and the
standard deviation, respectively, of all measurements within the
plate. Normalization of raw data removes systematic plate-to-plate
variation, making measurements comparable across plates. Statis-
tical analyses for the cross-strain validation studies, the reporter
studies, and miRNA studies were performed using GraphPad
Prism software using the Mann-Whitney U test.
Supporting Information
Figure S1 Calculated standard deviation of the z-scores
of the human protease library. The primary screen provided
two independent studies and was analyzed using a scaling
methodology that sets the non-targeting control siRNA (siNEG)
at an arbitrary value of 1.0, and the negative control siTOX at
zero. siRNAs targeting host genes were assigned a score based on
the distribution of these values. Wells in the primary screen with a
percent of differentiation greater than 1.5 standard deviations
above the plate mean in both duplicates were considered primary
hits. Of the 481 HP genes targeted, 24 were genes were identified
as ‘‘primary hits’’.
(TIF)
Figure S2 siRNA treatment decreases protein levels of
the target protease genes. A: A549 cells were untreated
(A549), treated with 50 nM of siNEG, or 50 nM of the
appropriate siRNA. After 72 hours, cells were lysed in 1%
TritonX-100 and protease gene levels were assessed by Western
blot. B: Protein levels of the protease genes were determined by
densitometry. Band density is shown as a percentage of the
untreated A549 cells.
(TIF)
Figure S3 An Ingenuity pathway analysis linked global
cellular pathways and the host protease genes of
interest. Hit protease genes (ADAMTS7, CPE, DPP3, MST1,
and PRSS12) are shown in red and relevant influenza proteins are
shown in green. Nodes indicating global cellular pathways linked
with the hit genes are shown in yellow (CREB, NF-kB, caspases).
(TIF)
Figure S4 miRNAs interact with host protease genes. An
Ingenuity pathway analysis implicated several miRNAs connected
with host protease genes of interest. Hit protease genes are shown
in red and miRNAs are shown in green.
(TIF)
Table S1 Expression ratios for pro- and anti-apoptotic
genes in A549 cells treated with siRNA for protease gene
targets
a,b.
aGene expression in A549 cells treated with 50 nM of
the appropriate siRNA was compared to cells treated with 50 nM
of siNEG. The experiment was performed as described in Figure 4.
bGene expression was normalized to GAPDH. *p,0.05.
(DOCX)
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